Skip to main content
Erschienen in: Endocrine 2/2013

01.04.2013 | Viewpoint

Common pathophysiological mechanisms involved in luteal phase deficiency and polycystic ovary syndrome. Impact on fertility

verfasst von: Georgios Boutzios, Maria Karalaki, Evangelia Zapanti

Erschienen in: Endocrine | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Luteal phase deficiency (LPD) is a consequence of the corpus luteum (CL) inability to produce and preserve adequate levels of progesterone. This is clinically manifested by short menstrual cycles and infertility. Abnormal follicular development, defects in neo-angiogenesis or inadequate steroidogenesis in the lutein cells of the CL have been implicated in CL dysfunction and LPD. LPD and polycystic ovary syndrome (PCOS) are independent disorders sharing common pathophysiological profiles. Factors such as hyperinsulinemia, AMH excess, and defects in angiogenesis of CL are at the origin of both LPD and PCOS. In PCOS ovulatory cycles, infertility could result from dysfunctional CL. The aim of this review was to investigate common mechanisms of infertility in CL dysfunction and PCOS.
Literatur
1.
Zurück zum Zitat G.E. Jones, Some newer aspects of management of infertility. J. Am. Med. Assoc. 141, 1123–1129 (1949)PubMedCrossRef G.E. Jones, Some newer aspects of management of infertility. J. Am. Med. Assoc. 141, 1123–1129 (1949)PubMedCrossRef
2.
Zurück zum Zitat W. Wuttke, L. Pitzel, D. Seidlova-Wuttke, B. Hinney, LH pulses and the corpus luteum: the luteal phase deficiency. Vitam. Horm. 63, 131–158 (2001)PubMedCrossRef W. Wuttke, L. Pitzel, D. Seidlova-Wuttke, B. Hinney, LH pulses and the corpus luteum: the luteal phase deficiency. Vitam. Horm. 63, 131–158 (2001)PubMedCrossRef
3.
Zurück zum Zitat E. Diamanti-Kandarakis, C.R. Kouli, A.T. Bergiele, F.A. Filandra, T.C. Tsianateli, G.G. Spina, E.D. Zapanti, M.I. Bartzis, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84, 4006–4011 (1999)CrossRef E. Diamanti-Kandarakis, C.R. Kouli, A.T. Bergiele, F.A. Filandra, T.C. Tsianateli, G.G. Spina, E.D. Zapanti, M.I. Bartzis, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84, 4006–4011 (1999)CrossRef
4.
Zurück zum Zitat Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)CrossRef Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)CrossRef
5.
Zurück zum Zitat S.F. Witchel, S.E. Recabarren, F. González, E. Diamanti-Kandarakis, K.I. Cheang, A.J. Duleba, R.S. Legro, R. Homburg, R. Pasquali, R.A. Lobo, C.C. Zouboulis, F. Kelestimur, F. Fruzzetti, W. Futterweit, R.J. Norman, D.H. Abbott, Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine (2012). doi:10.1007/s12020-012-9701-4 PubMed S.F. Witchel, S.E. Recabarren, F. González, E. Diamanti-Kandarakis, K.I. Cheang, A.J. Duleba, R.S. Legro, R. Homburg, R. Pasquali, R.A. Lobo, C.C. Zouboulis, F. Kelestimur, F. Fruzzetti, W. Futterweit, R.J. Norman, D.H. Abbott, Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine (2012). doi:10.​1007/​s12020-012-9701-4 PubMed
6.
Zurück zum Zitat M.J. De Souza, B.E. Miller, A.B. Loucks, A.A. Luciano, L.S. Pescatello, C.G. Campbell, B.L. Lasley, High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. J. Clin. Endocrinol. Metab. 83, 4220–4232 (1998)PubMedCrossRef M.J. De Souza, B.E. Miller, A.B. Loucks, A.A. Luciano, L.S. Pescatello, C.G. Campbell, B.L. Lasley, High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. J. Clin. Endocrinol. Metab. 83, 4220–4232 (1998)PubMedCrossRef
7.
8.
Zurück zum Zitat E. Diamanti-Kandarakis, C. Christakou, E. Marinakis, Phenotypes and environmental factors: their influence in PCOS. Curr. Pharm. Des. 18, 270–282 (2012)PubMedCrossRef E. Diamanti-Kandarakis, C. Christakou, E. Marinakis, Phenotypes and environmental factors: their influence in PCOS. Curr. Pharm. Des. 18, 270–282 (2012)PubMedCrossRef
9.
Zurück zum Zitat J.E. Nestler, Metformin for the treatment of the polycystic ovary syndrome. N. Engl. J. Med. 358, 47–54 (2008)PubMedCrossRef J.E. Nestler, Metformin for the treatment of the polycystic ovary syndrome. N. Engl. J. Med. 358, 47–54 (2008)PubMedCrossRef
10.
Zurück zum Zitat R. Tsutsumi, N.J. Webster, GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr. J. 56, 729–737 (2009)PubMedCrossRef R. Tsutsumi, N.J. Webster, GnRH pulsatility, the pituitary response and reproductive dysfunction. Endocr. J. 56, 729–737 (2009)PubMedCrossRef
11.
Zurück zum Zitat R. Joseph-Horne, H. Mason, S. Batty, D. White, S. Hillier, M. Urquhart, S. Franks, Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum. Reprod. 17, 1459–1463 (2002)PubMedCrossRef R. Joseph-Horne, H. Mason, S. Batty, D. White, S. Hillier, M. Urquhart, S. Franks, Luteal phase progesterone excretion in ovulatory women with polycystic ovaries. Hum. Reprod. 17, 1459–1463 (2002)PubMedCrossRef
12.
Zurück zum Zitat G.F. Erickson, D.A. Magoffin, V.G. Garzo, A.P. Cheung, R.J. Chang, Granulosa cells of polycystic ovaries: are they normal or abnormal? Hum. Reprod. 7, 293–299 (1992)PubMed G.F. Erickson, D.A. Magoffin, V.G. Garzo, A.P. Cheung, R.J. Chang, Granulosa cells of polycystic ovaries: are they normal or abnormal? Hum. Reprod. 7, 293–299 (1992)PubMed
13.
Zurück zum Zitat P. Fedorcsak, R. Storeng, P.O. Dale, T. Tanbo, T. Abyholm, Impaired insulin action on granulosa-lutein cells in women with polycystic ovary syndrome and insulin resistance. Gynecol. Endocrinol. 14, 327–336 (2000)PubMedCrossRef P. Fedorcsak, R. Storeng, P.O. Dale, T. Tanbo, T. Abyholm, Impaired insulin action on granulosa-lutein cells in women with polycystic ovary syndrome and insulin resistance. Gynecol. Endocrinol. 14, 327–336 (2000)PubMedCrossRef
14.
Zurück zum Zitat S. Rice, N. Christoforidis, C. Gadd, D. Nikolaou, L. Seyani, A. Donaldson, R. Margara, K. Hardy, S. Franks, Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 20, 373–381 (2005)PubMedCrossRef S. Rice, N. Christoforidis, C. Gadd, D. Nikolaou, L. Seyani, A. Donaldson, R. Margara, K. Hardy, S. Franks, Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 20, 373–381 (2005)PubMedCrossRef
15.
Zurück zum Zitat J.M. Weiss, S. Polack, K. Diedrich, O. Ortmann, Effects of insulin on luteinizing hormone and prolactin secretion and calcium signaling in female rat pituitary cells. Arch. Gynecol. Obstet. 269, 45–50 (2003)PubMedCrossRef J.M. Weiss, S. Polack, K. Diedrich, O. Ortmann, Effects of insulin on luteinizing hormone and prolactin secretion and calcium signaling in female rat pituitary cells. Arch. Gynecol. Obstet. 269, 45–50 (2003)PubMedCrossRef
16.
Zurück zum Zitat K.J. Meenakumari, S. Agarwal, A. Krishna, L.K. Pandey, Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Braz. J. Med. Biol. Res. 37, 1637–1644 (2004)PubMedCrossRef K.J. Meenakumari, S. Agarwal, A. Krishna, L.K. Pandey, Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. Braz. J. Med. Biol. Res. 37, 1637–1644 (2004)PubMedCrossRef
17.
Zurück zum Zitat A. La Marca, F.J. Broekmans, A. Volpe, B.C. Fauser, N.S. Macklon, Anti-Müllerian hormone (AMH): what do we still need to know? Hum. Reprod. 24, 2264–2275 (2009)PubMedCrossRef A. La Marca, F.J. Broekmans, A. Volpe, B.C. Fauser, N.S. Macklon, Anti-Müllerian hormone (AMH): what do we still need to know? Hum. Reprod. 24, 2264–2275 (2009)PubMedCrossRef
18.
Zurück zum Zitat A. Munsterberg, R. Lovell-Badge, Expression of the mouse anti-mullerian hormone gene suggests a role in both male and female sexual differentiation. Development 113, 613–624 (1991)PubMed A. Munsterberg, R. Lovell-Badge, Expression of the mouse anti-mullerian hormone gene suggests a role in both male and female sexual differentiation. Development 113, 613–624 (1991)PubMed
19.
Zurück zum Zitat A.P.N. Themmen, Anti-Müllerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J. Natl. Cancer Inst. Monogr. 34, 18–21 (2005)PubMedCrossRef A.P.N. Themmen, Anti-Müllerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J. Natl. Cancer Inst. Monogr. 34, 18–21 (2005)PubMedCrossRef
20.
Zurück zum Zitat S.A. Stubbs, K. Hardy, P. Da Silva-Buttkus, J. Stark, L.J. Webber, A.M. Flanagan, A.P. Themmen, J.A. Visser, N.P. Groome, S. Franks, Anti-Müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J. Clin. Endocrinol. Metab. 90, 5536–5543 (2005)PubMedCrossRef S.A. Stubbs, K. Hardy, P. Da Silva-Buttkus, J. Stark, L.J. Webber, A.M. Flanagan, A.P. Themmen, J.A. Visser, N.P. Groome, S. Franks, Anti-Müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J. Clin. Endocrinol. Metab. 90, 5536–5543 (2005)PubMedCrossRef
21.
Zurück zum Zitat P. Pigny, E. Merlen, Y. Robert, C. Cortet-Rudelli, C. Decanter, S. Jonard, D. Dewailly, Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J. Clin. Endocrinol. Metab. 88, 5957–5962 (2003)PubMedCrossRef P. Pigny, E. Merlen, Y. Robert, C. Cortet-Rudelli, C. Decanter, S. Jonard, D. Dewailly, Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J. Clin. Endocrinol. Metab. 88, 5957–5962 (2003)PubMedCrossRef
22.
Zurück zum Zitat D.S. Wachs, M.S. Coffler, P.J. Malcom, R.J. Chang, Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J. Clin. Endocrinol. Metab. 92, 1871–1874 (2007)PubMedCrossRef D.S. Wachs, M.S. Coffler, P.J. Malcom, R.J. Chang, Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J. Clin. Endocrinol. Metab. 92, 1871–1874 (2007)PubMedCrossRef
23.
Zurück zum Zitat J.H. Kim, M.M. Seibel, D.T. MacLaughlin, P.K. Donahoe, B.J. Ransil, P.A. Hametz, C.J. Richards, The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J. Clin. Endocrinol. Metab. 75, 911–917 (1992)PubMedCrossRef J.H. Kim, M.M. Seibel, D.T. MacLaughlin, P.K. Donahoe, B.J. Ransil, P.A. Hametz, C.J. Richards, The inhibitory effects of müllerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J. Clin. Endocrinol. Metab. 75, 911–917 (1992)PubMedCrossRef
24.
Zurück zum Zitat L. Pellatt, S. Rice, H.D. Mason, Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 139, 825–833 (2010)PubMedCrossRef L. Pellatt, S. Rice, H.D. Mason, Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction 139, 825–833 (2010)PubMedCrossRef
25.
Zurück zum Zitat M.P. Grossman, S.T. Nakajima, M.E. Fallat, Y. Siow, Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil. Steril. 89, 1364–1370 (2008)PubMedCrossRef M.P. Grossman, S.T. Nakajima, M.E. Fallat, Y. Siow, Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil. Steril. 89, 1364–1370 (2008)PubMedCrossRef
26.
Zurück zum Zitat L.P. Reynolds, A.T. Grazul-Bilska, D.A. Redmer, Angiogenesis in the corpus luteum. Endocrine 12, 1–9 (2001)CrossRef L.P. Reynolds, A.T. Grazul-Bilska, D.A. Redmer, Angiogenesis in the corpus luteum. Endocrine 12, 1–9 (2001)CrossRef
27.
Zurück zum Zitat H.M. Fraser, C. Wulff, Angiogenesis in the corpus luteum. Reprod. Biol. Endocrinol. 1, 88 (2003)PubMedCrossRef H.M. Fraser, C. Wulff, Angiogenesis in the corpus luteum. Reprod. Biol. Endocrinol. 1, 88 (2003)PubMedCrossRef
28.
Zurück zum Zitat N. Ferrara, G. Frantz, J. LeCouter, L. Dillard-Telm, T. Pham, A. Draksharapu, T. Giordano, F. Peale, Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am. J. Pathol. 162, 1881–1893 (2003)PubMedCrossRef N. Ferrara, G. Frantz, J. LeCouter, L. Dillard-Telm, T. Pham, A. Draksharapu, T. Giordano, F. Peale, Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am. J. Pathol. 162, 1881–1893 (2003)PubMedCrossRef
29.
Zurück zum Zitat A. Galvao, S. Henriques, D. Pestka, K. Lukasik, D. Skarzynski, L.M. Mateus, G.M. Ferreira-Dias, Equine luteal function regulation may depend on the interaction between cytokines and vascular endothelial growth factor: an in vitro study. Biol. Reprod. 86, 1–9 (2012)CrossRef A. Galvao, S. Henriques, D. Pestka, K. Lukasik, D. Skarzynski, L.M. Mateus, G.M. Ferreira-Dias, Equine luteal function regulation may depend on the interaction between cytokines and vascular endothelial growth factor: an in vitro study. Biol. Reprod. 86, 1–9 (2012)CrossRef
30.
Zurück zum Zitat M.B. Stanek, S.M. Borman, T.A. Molskness, J.M. Larson, R.L. Stouffer, P.E. Patton, Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women. J. Clin. Endocrinol. Metab. 92, 2726–2733 (2007)PubMedCrossRef M.B. Stanek, S.M. Borman, T.A. Molskness, J.M. Larson, R.L. Stouffer, P.E. Patton, Insulin and insulin-like growth factor stimulation of vascular endothelial growth factor production by luteinized granulosa cells: comparison between polycystic ovarian syndrome (PCOS) and non-PCOS women. J. Clin. Endocrinol. Metab. 92, 2726–2733 (2007)PubMedCrossRef
Metadaten
Titel
Common pathophysiological mechanisms involved in luteal phase deficiency and polycystic ovary syndrome. Impact on fertility
verfasst von
Georgios Boutzios
Maria Karalaki
Evangelia Zapanti
Publikationsdatum
01.04.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9778-9

Weitere Artikel der Ausgabe 2/2013

Endocrine 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.